Tadalafil effect on metabolic syndrome-associated bladder alterations: An experimental study in a rabbit model

Journal of Sexual Medicine

Volumn 11, Issue 5, 2014, Pages 1159-1172

  Vignozzi, Linda ^a   Filippi, Sandra ^a   Comeglio, Paolo ^a   Cellai, Ilaria ^a   Morelli, Annamaria ^a   Maneschi, Elena ^a   Sarchielli, Erica ^a   Gacci, Mauro ^a   Carini, Marco ^a   Vannelli, Gabriella Barbara ^a   Maggi, Mario ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

LUTS; Metabolic syndrome; OAB; Prostatic enlargement; Rabbit bladder; RhoA ROCK signaling; Tadalafil

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; CHOLESTEROL; ESTRADIOL; RHO KINASE; TADALAFIL; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER; BLADDER DETRUSOR HYPERCONTRACTILITY; CHEMOTAXIS ASSAY; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; DRUG EFFECT; EXPERIMENTAL RABBIT; EXPERIMENTAL STUDY; FIBROSIS; GLUCOSE INTOLERANCE; HYPERGLYCEMIA; HYPOGONADISM; HYPOXIA; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTRAABDOMINAL FAT; LIPID DIET; LOWER URINARY TRACT SYMPTOM; MALE; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PROSTATE WEIGHT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEMINAL VESICLE; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTILITY; SMOOTH MUSCLE FIBER; TESTIS; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

LUTS; METABOLIC SYNDROME; OAB; PROSTATIC ENLARGEMENT; RABBIT BLADDER; RHOA/ROCK SIGNALING; TADALAFIL;

AMIDES; ANIMALS; CARBOLINES; DIET, HIGH-FAT; ENZYME INHIBITORS; MALE; METABOLIC SYNDROME X; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PYRIDINES; RABBITS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; UP-REGULATION; URINARY BLADDER DISEASES; UROLOGICAL AGENTS;

EID: 84899479024     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12478     Document Type: Article

References (60)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A. Standardisation Sub-Committee of the International Continence Society. The standardization of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49.
2. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006;49:651-658.
3. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006;50:1306-1314.
4. Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, Wyndaele JJ, Melby T, Viktrup L. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action. Neurourol Urodyn 2011;30:292-301.
5. Hammarsten J, Peeker R. Urological aspects of the metabolic syndrome. Nat Rev Urol 2011;8:483-494.
6. Laven BA, Orsini N, Andersson SO, Johansson JE, Gerber GS, Wolk A. Birth weight, abdominal obesity and the risk of lower urinary tract symptoms in a population based study of Swedish men. J Urol 2008;179:1891-1895.
7. Michel MC, Heemann U, Schumacher H, Mehlburger L, Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol 2004;172:1390-1393.
8. Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 2000;163:1725-1729.
9. Tomita K, Mizoue T, Matsumoto T. Lower urinary tract symptoms in relation to lifestyle and medical conditions in Japanese workers. Int J Urol 2009;16:493-498.
10. Martin SA, Haren MT, Marshall VR, Lange K, Wittert GA. Members of the Florey Adelaide Male Ageing Study. Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J Urol 2011;29:179-184.
11. Vignozzi L, Gacci M, Cellai I, Santi R, Corona G, Morelli A, Rastrelli G, Comeglio P, Sebastianelli A, Maneschi E, Nesi G, De Nunzio C, Tubaro A, Mannucci E, Carini M, Maggi M. Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate 2013;73:789-800.
12. Gacci M, Vignozzi L, Sebastianelli A, Salvi M, Giannessi C, De Nunzio C, Tubaro A, Corona G, Rastrelli G, Santi R, Nesi G, Serni S, Carini M, Maggi M. Metabolic syndrome and lower urinary tract symptoms: The role of inflammation. Prostate Cancer Prostatic Dis 2013;16:101-106.
13. Krajewska M, Banares S, Zhang EE, Huang X, Scadeng M, Jhala US, Feng GS, Krajewski G. Development of diabesity in mice with neuronal deletion of Shp2 tyrosine phosphatase. Am J Pathol 2008;172:1312-1324.
14. Norton P, Milsom I. Genetics and the lower urinary tract. Neurourol Urodyn 2010;29:609-611.
15. Rahman NU, Phonsombat S, Bochinski D, Carrion RE, Nunes L, Lue TF. An animal model to study lower urinary tract symptoms and erectile dysfunction: The hyperlipidaemic rat. BJU Int 2007;100:658-663.
16. Azadzoi KM, Tarcan T, Siroky MB, Krane RJ. Atherosclerosis-induced chronic ischemia causes bladder fibrosis and non-compliance in the rabbit. J Urol 1999;161:1626-1635.
17. Tong YC, Cheng JT. Alterations of M 2, 3 -Muscarinic Receptor Protein and mRNA Expression in the Bladder of the Fructose Fed Obese Rat. Urology 2007;178:1537-1542.
18. Tong YC, Chin WT, Cheng JT. Alterations in M2-muscarinic receptor protein and mRNA in diabetic rat urinary bladders. NeurosciLett 1999;277:173-176.
19. Tong YC, Cheng JT. Alteration of M3 subtype muscarinic receptors in the rat urinary bladder. Pharmacology 2001;64:148-151.
20. Filippi S, Vignozzi L, Morelli A, Chavalmane AK, Sarchielli E, Fibbi B, Saad F, Sandner P, Ruggiano P, Vannelli GB, Mannucci E, Maggi M. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med 2009;6:3274-3288.
21. Vignozzi L, Morelli A, Filippi S, Comeglio P, Chavalmane AK, Marchetta M, Toce M, Yehiely-Cohen R, Vannelli GB, Adorini L, Maggi M. Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. J Sex Med 2011;8:57-77.
22. Vignozzi L, Morelli A, Sarchielli E, Comeglio P, Filippi S, Cellai I, Maneschi E, Serni S, Gacci M, Carini M, Piccinni MP, Saad F, Adorini L, Vannelli GB, Maggi M. Testosterone protects from metabolic syndrome-associated prostate inflammation: An experimental study in rabbit. J Endocrinol 2012;212:71-84.
23. Morelli A, Comeglio P, Filippi S, Sarchielli E, Cellai I, Vignozzi L, Yehiely-Cohen R, Maneschi E, Gacci M, Carini M, Adorini L, Vannelli GB, Maggi M. Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome. J Steroid Biochem Mol Biol 2012;132:80-92.
24. Maneschi E, Vignozzi L, Morelli A, Mello T, Filippi S, Cellai I, Comeglio P, Sarchielli E, Calcagno A, Mazzanti B, Vettor R, Vannelli GB, Adorini L, Maggi M. FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS. J Endocrinol 2013;218:215-231.
25. Morelli A, Comeglio P, Filippi S, Sarchielli E, Vignozzi L, Maneschi E, Cellai I, Gacci M, Lenzi A, Vannelli GB, Maggi M. Mechanism of action of phosphodiesterasetype 5 inhibition in metabolic syndrome-associated prostate alterations: An experimental study in the rabbit. Prostate 2013;73:428-441.
26. Morelli A, Vignozzi L, Filippi S, Vannelli GB, Ambrosini S, Mancina R, Crescioli C, Donati S, Fibbi B, Colli E, Adorini L, Maggi M. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Prostate 2007;67:234-247.
27. De Lean A, Munson PJ, Rodbard D. Simultaneous analysis of families of sigmoidal curves: Applications to biossay, radioligand assay, and physiological dose-response curves. Am J Physiol 1978;235:97-102.
28. Small EM. The actin-MRTF-SRF gene regulatory axis and myofibroblast differentiation. J Cardiovasc Transl Res. 2012;5:794-804.
29. Zhao Z, Manser E. PAK and other Rho-associated kinases-effectors with surprisingly diverse mechanisms of regulation. Biochem J 2005;386:201-214.
30. Feng J, Ito M, Ichikawa K, Isaka N, Nishikawa M, Hartshorne DJ, Nakano T. inhibitory phosphorylation site for rho-associated kinase on smooth muscle myosin phosphatase. J Biol Chem 1999;52:37385-37390.
31. Somlyo AP, Somlyo AV. Ca2{thorn} sensitivity of smooth muscle and nonmuscle myosin II: Modulated by g proteins, kinases, and myosin phosphatase. Physiol Rev 2003;83:1325-1358.
32. Andersson K-E, Wein AJ. Pharmacology of the lower urinary tract: Basis for current and future treatments of urinary incontinence. Pharmacol Rev 2004;56:581-631.
33. Wibberley A, Chen Z, Hu E, Hieble JP, Westfall TD. Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle. Br J Pharmacol 2003;138:757-766.
34. Fleichman M, Schneider T, Fetscher C, Michel MC. Signal transduction underlying carbachol-induced contraction of rat urinary bladder. II. Protein kinases. J Pharmacol Exp Ther 2004;308:54-58.
35. Schneider T, Hein P, Michel MC. Signal transduction underlying carbachol-induced contraction of rat urinary bladder. I. Phospholipases and Ca2{thorn} sources. J Pharmacol Exp Ther 2004;308:47-53.
36. Takahashi R, Nishimura J, Hirano K, Seki N, Naito S, Kanaide H. Ca2{thorn} sensitization in contraction of human bladder smooth muscle. J Urol 2004;172:748-752.
37. Takahashi N, Shiomi H, Kushida N, etal. Obstruction alters muscarinic receptor-coupled RhoA/Rho-kinase pathway in the urinary bladder of the rat. Neurourol Urodyn 2009;28:257-262.
38. Inoue S, Saito M, Takenaka A. Hydroxyfasudil ameliorates bladder dysfunction in male spontaneously hypertensive rats. Urology 2012;79:1186 e9-14.
39. Masago T, Watanabe T, Saito M, Kinoshita Y, Sato K, Miyagawa I. Effect of the rho-kinase inhibitor hydroxyfasudil on bladder overactivity: An experimental rat model. Int J Urol 2009;16:842-847.
40. Soler R, Andersson KE, Chancellor MB, Chapple CR, de Groat WC, Drake MJ, Gratzke C, Lee R, Cruz F. Future direction in pharmacotherapy for Non-neurogenic male lower urinary tract symptoms. Eur Urol 2013;64:610-621.
41. Wang Z, Cheng Z, Cristofaro V, Li J, Xiao X, Gomez P, Ge R, Gong E, Strle K, Sullivan MP, Adam RM, White MF, Olumi AF. Inhibition of TNF-α improves the bladder dysfunction that is associated with type 2 diabetes. Diabetes 2012;61:2134-2145.
42. Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994-1003.
43. Giuliano F, Ückert S, Maggi M, Birder L, Kissel J, Viktrup L. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 2013;63:506-516.
44. Porst H, Roehrborn CG, Secrest RJ, Esler A, Viktrup L. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies. J Sex Med 2013;10:2044-2052.
45. Angulo J, Cuevas P, Fernández A, La Fuente JM, Allona A, Moncada I, Sáenz de Tejada I. Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck. J Sex Med 2012;9:2293-2306.
46. Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, Wong DG, Secrest RJ. Tadalafil 2.5 or 5mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: Results of a randomized, placebo-controlled, double-blind study. J Sex Med 2012;9:271-281.
47. Bechara A, Casabe A, Rodriguez Baigorri G, Cobreros C. Effectiveness of Tadalafil 5mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: Results from naturalistic observational TadaLutsEd study. J Sex Med 2014;11:498-505.
48. Singh DV, Mete UK, Mandal AK, Singh SK. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and Tadalafil versus Tamsulosin or Tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. J Sex Med 2014;11:187-196.
49. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, Gacci M, Vignozzi L, Vannelli GB, Carini M, Forti G, Maggi M. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007;148:1019-1029.
50. Zhao C, Kim SH, Lee SW, Jeon JH, Kang KK, Choi SB, Park JK. Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Br J Urol Int 2011;107:1943-1947.
51. Morelli A, Filippi S, Comeglio P, Sarchielli E, Chavalmane AK, Vignozzi L, Fibbi B, Silvestrini E, Sandner P, Gacci M, Carini M, Vannelli GB, Maggi M. Acute vardenafil administration improbe bladder oxygenation in spontaneously hypertensive rats. J Sex Med 2010;7:107-120.
52. Morelli A, Sarchielli E, Comeglio P, Filippi S, Mancina R, Gacci M, Vignozzi L, Carini M, Vannelli GB, Maggi M. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med 2011;8:2746-2760.
53. Morelli A, Filippi S, Sandner P, Fibbi B, Chavalmane AK, Silvestrini E, Sarchielli E, Vignozzi L, Gacci M, Carini M, Vannelli GB, Maggi M. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. J Sex Med 2009;6:1594-1608.
54. Vignozzi L, Filippi S, Morelli A, Comeglio P, Cellai I, Sarchielli E, Maneschi E, Mancina R, Gacci M, Vannelli GB, Maggi M. Testosterone/estradiol ratio regulates NO-inducedbladderrelaxation and responsiveness to PDE5 inhibitors. J Sex Med 2012;9:3028-3040.
55. Comeglio P, Morelli A, Cellai I, Vignozzi L, Sarchielli E, Filippi S, Maneschi E, Corcetto F, Corno C, Gacci M, Vannelli GB, Maggi M. Opposite effects of tamoxifen on metabolicsyndrome-induced bladder and prostate alterations: A role for GPR30/GPER? Prostate 2014;74:10-28.
56. Chavalmane AK, Comeglio P, Morelli A, Filippi S, Fibbi B, Vignozzi L, Sarchielli E, Marchetta M, Failli P, Sandner P, Saad F, Gacci M, Vannelli GB, Maggi M. Sex steroid receptors in male human bladder: expression and biological function. J Sex Med 2010;7:2698-2713.
57. Aversa A, Caprio M, Antelmi A, Armani A, Brama M, Greco EA, Francomano D, Calanchini M, Spera G, Di Luigi L, Rosano GM, Lenzi A, Migliaccio S, Fabbri A. Exposure to phosphodiesterase type 5 inhibitors stimulates aromatase expression in human adipocytes in vitro. J Sex Med 2011;8:696-704.
58. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, Parsons JT, Horwitz AR. Cell migration: Integrating signals from front to back. Science 2003;302:1704-1709.
59. Chardin P, Boquet P, Madaule P, Popoff MR, Rubin EJ, Gill DM. The mammalian G protein rhoC is ADP-ribosylated by Clostridium botulinum exoenzyme C3 and affects actin microfilaments in Vero cells. EMBO J 1989;8:1087-1092.
60. Liu XM, Peyton KJ, Wang X, Durante W. Sildenafil stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells via distinct signaling pathways. Biochem Pharmacol 2012;84:1045-1054.